Surgery Today

, Volume 44, Issue 5, pp 976–981 | Cite as

Severe postoperative hemorrhage caused by antibody-mediated coagulation factor deficiencies: report of two cases

  • Tomoya Miura
  • Daisuke Ban
  • Takatoshi Koyama
  • Atsushi Kudo
  • Takanori Ochiai
  • Takumi Irie
  • Noriaki Nakamura
  • Shinji Tanaka
  • Shigeki Arii
Case Report

Abstract

Antibody-mediated coagulation factor deficiencies constitute a rare disorder that may develop in elderly patients without any history of a bleeding diathesis. Patients may present with severe and sometimes catastrophic bleeding. We report two cases of postoperative hemorrhage caused by a coagulation factor deficiency. In Case 1, massive intraabdominal bleeding occurred on day 3 after pancreaticoduodenectomy for bile duct cancer, and was caused by an acquired inhibitor of coagulation factor VIII. Hemostasis was achieved and the factor VIII inhibitor titer decreased to zero with activated prothrombin complex concentrates, prednisolone, and cyclophosphamide. In Case 2, intraabdominal bleeding occurred on day 7 after hepatectomy for hepatocellular carcinoma, and was caused by an acquired inhibitor against factors II (prothrombin) and V. This patient was treated with hemostatic agents containing bovine thrombin during surgery and also with prednisolone. We report these cases to highlight that antibody-mediated coagulation factor deficiencies should be considered when an elderly patient suffers sudden postoperative hemorrhage and to stress the importance of prompt diagnosis because of the risk of potentially life-threatening hemorrhage.

Keywords

Postoperative hemorrhage Coagulation factor deficiencies Acquired hemophilia 

Notes

Acknowledgments

We thank Dr Midori Shima, Department of Pediatrics, Nara Medical University, Nara, Japan for assessment of the inhibitors.

References

  1. 1.
    Zealley IA, Tait IS, Polignano FM. Delayed massive hemorrhage after pancreatic and biliary surgery: embolization or surgery? Ann Surg. 2006;243:138–9.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Choi SH, Moon HJ, Heo JS, Joh JW, Kim YI. Delayed hemorrhage after pancreaticoduodenectomy. J Am Coll Surg. 2004;199:186–91.PubMedCrossRefGoogle Scholar
  3. 3.
    Collins P, Macartney N, Davies R, Lees S, Giddings J, Majer R. A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br J Haematol. 2004;124:86–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, Keeling DM, Liesner R, Brown SA, Hay CR, UK Haemophilia Centre Doctors’ Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood. 2007;109:1870–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost. 1981;45:200–3.PubMedGoogle Scholar
  6. 6.
    Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood. 1993;81:1513–20.PubMedGoogle Scholar
  7. 7.
    Nesheim ME, Nichols WL, Cole TL, Houston JG, Schenk RB, Mann KG, Bowie EJ. Isolation and study of an acquired inhibitor of human coagulation factor V. J Clin Invest. 1986;77:405–15.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Reitter S, Knoebl P, Pabinger I, Lechner K. Postoperative paraneoplastic factor VIII auto-antibodies in patients with solid tumours. Haemophilia. 2011;17:e889–94.PubMedGoogle Scholar
  9. 9.
    Brack A, Vögeler S, Hilpert J, Berger G, Buhr HJ, Koscielny J. Acquired factor VIII inhibitor. Anesthesiology. 2009;111:1151–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Brzoska M, Krause M, Geiger H, Betz C. Immunoadsorption with single-use columns for the management of bleeding in acquired hemophilia A: a series of nine cases. J Clin Apher. 2007;22:233–40.PubMedCrossRefGoogle Scholar
  11. 11.
    Theodossiades G, Tsevrenis V, Nomikou E, Dadiotis L, Kontopoulou-Griva I. Surgery-associated acquired hemophilia A. Ann Hematol. 2001;80:691–3.PubMedCrossRefGoogle Scholar
  12. 12.
    Rice L. Surreptitious bleeding in surgery: a major challenge in coagulation. Clin Lab Haematol. 2000;22:17–20.PubMedCrossRefGoogle Scholar
  13. 13.
    Harada Y, Iwai M, Miyoshi M, Ueda Y, Mitsufuji S, Seiki K, Harada M, Kashima K. Life-threatening hemorrhage in a patient with gastric cancer and acquired hemophilia. Am J Gastroenterol. 1998;93:1372–3.PubMedCrossRefGoogle Scholar
  14. 14.
    Hosoya Y, Matsumura M, Madoiwa S, Zuiki T, Matsumoto S, Nunomiya S, Lefor A, Sata N, Yasuda Y. Acquired hemophilia A caused by factor VIII inhibitors: report of a case. Surg Today 2012;14.Google Scholar
  15. 15.
    Onishi I, Kayahara M, Munemoto M, Sakai S, Makino I, Hayashi H, Nakagawara H, Tajima H, Takamura H, Kitagawa H, Tani T, Ohta T. Management of postoperative hemorrhage associated with factor VIII inhibitor: report of a case. Surg Today 2012;12.Google Scholar
  16. 16.
    Sallah S, Wan JY. Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients. Cancer. 2001;91:1067–74.PubMedCrossRefGoogle Scholar
  17. 17.
    Ortel TL, Charles LA, Keller FG, Marcom PK, Oldham HN Jr, Kane WH, Macik BG. Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis. Am J Hematol. 1994;45:128–35.PubMedCrossRefGoogle Scholar
  18. 18.
    Rapaport SI, Zivelin A, Minow RA, Hunter CS, Donnelly K. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol. 1992;97:84–91.PubMedGoogle Scholar
  19. 19.
    Bänninger H, Hardegger T, Tobler A, Barth A, Schüpbach P, Reinhart W, Lämmle B, Furlan M. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br J Haematol. 1993;85:528–32.PubMedCrossRefGoogle Scholar
  20. 20.
    Carroll JF, Moskowitz KA, Edwards NM, Hickey TJ, Rose EA, Budzynski AZ. Immunologic assessment of patients treated with bovine fibrin as a hemostatic agent. Thromb Haemost. 1996;76:925–31.PubMedGoogle Scholar
  21. 21.
    Madoiwa S, Nakamura Y, Mimuro J, Furusawa S, Koyama T, Sugo T, Matsuda M, Sakata Y. Autoantibody against prothrombin aberrantly alters the proenzyme to facilitate formation of a complex with its physiological inhibitor antithrombin III without thrombin conversion. Blood. 2001;97:3783–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Kajitani M, Ozdemir A, Aguinaga M, Jazieh AR, Flick JT, Antakli T. Severe hemorrhagic complication due to acquired factor V inhibitor after single exposure to bovine thrombin product. J Card Surg. 2000;15:378–82.PubMedCrossRefGoogle Scholar
  23. 23.
    Huth-Kuhne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Levesque H, Castellano ME, Shima M, St-Louis J. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica. 2009;94:566–75.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol. 2006;133:591–605.PubMedCrossRefGoogle Scholar
  25. 25.
    Rivard GE, St Louis J, Lacroix S, Champagne M, Rock G. Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution. Haemophilia. 2003;9:711–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2013

Authors and Affiliations

  • Tomoya Miura
    • 1
  • Daisuke Ban
    • 1
  • Takatoshi Koyama
    • 2
  • Atsushi Kudo
    • 1
  • Takanori Ochiai
    • 1
  • Takumi Irie
    • 1
  • Noriaki Nakamura
    • 1
  • Shinji Tanaka
    • 1
  • Shigeki Arii
    • 1
  1. 1.Department of Hepatobiliary-Pancreatic Surgery, Graduate School of MedicineTokyo Medical and Dental UniversityTokyoJapan
  2. 2.Graduate School of Health Care SciencesTokyo Medical and Dental UniversityTokyoJapan

Personalised recommendations